JP2023537229A5 - - Google Patents
Info
- Publication number
- JP2023537229A5 JP2023537229A5 JP2023503508A JP2023503508A JP2023537229A5 JP 2023537229 A5 JP2023537229 A5 JP 2023537229A5 JP 2023503508 A JP2023503508 A JP 2023503508A JP 2023503508 A JP2023503508 A JP 2023503508A JP 2023537229 A5 JP2023537229 A5 JP 2023537229A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- enhancement
- pharmaceutical composition
- innate immunity
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021030633 | 2020-07-18 | ||
| IN202021030633 | 2020-07-18 | ||
| IN202021054151 | 2020-12-12 | ||
| IN202021054151 | 2020-12-12 | ||
| PCT/IN2021/050325 WO2021199078A2 (en) | 2020-03-29 | 2021-03-30 | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19. |
| INPCT/IN2021/050325 | 2021-03-30 | ||
| PCT/IN2021/050699 WO2022018754A1 (en) | 2020-07-18 | 2021-07-19 | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537229A JP2023537229A (ja) | 2023-08-31 |
| JP2023537229A5 true JP2023537229A5 (cg-RX-API-DMAC7.html) | 2024-07-26 |
Family
ID=79728594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503508A Pending JP2023537229A (ja) | 2020-07-18 | 2021-07-19 | SARS-CoV-2タンパク質と宿主細胞の分子機構および細胞機構との相互作用、およびCOVID-19を処置するための製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240024337A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4181917A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023537229A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021313476A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3179022A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300014A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022018754A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115968375A (zh) * | 2020-03-29 | 2023-04-14 | 阿克西拉制药公司 | SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂 |
| AU2022204290A1 (en) * | 2020-12-12 | 2023-07-27 | Akseera Pharma Corp. | Cannabidiol for augmenting vaccine mediated immunity and prophylaxis of covid-19 |
| IL316127A (en) * | 2022-04-02 | 2024-12-01 | Akseera Pharma Corp | Enhancement of antiviral and anticancer therapies by combinations of poly(I:C) and cannabidiol. |
| WO2023195029A2 (en) * | 2022-04-07 | 2023-10-12 | Akseera Pharma Corp. | A method of use for cannabidiol in the prevention and treatment of interferon-responsive conditions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010226604A1 (en) * | 2009-03-19 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing |
| CN115968375A (zh) * | 2020-03-29 | 2023-04-14 | 阿克西拉制药公司 | SARS-CoV-2蛋白与宿主细胞的分子和细胞机制的相互作用以及治疗COVID-19的制剂 |
| WO2021209998A1 (en) * | 2020-04-14 | 2021-10-21 | Molad Ami | Composition for the treatment of respiratory symptoms and methods thereof |
| AU2020447636A1 (en) * | 2020-05-11 | 2022-12-08 | Add Advanced Drug Delivery Technologies Ltd. | Uses and formulations of cannabinoids |
| WO2021231810A1 (en) * | 2020-05-14 | 2021-11-18 | Augusta University Research Institute, Inc. | Cannabidiol as a therapeutic modality for covid-19 |
| CN120789031A (zh) * | 2020-07-24 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 大麻二酚在制备治疗冠状病毒感染的药物中的用途 |
-
2021
- 2021-03-30 CA CA3179022A patent/CA3179022A1/en active Pending
- 2021-07-19 WO PCT/IN2021/050699 patent/WO2022018754A1/en not_active Ceased
- 2021-07-19 CA CA3189802A patent/CA3189802A1/en active Pending
- 2021-07-19 AU AU2021313476A patent/AU2021313476A1/en active Pending
- 2021-07-19 IL IL300014A patent/IL300014A/en unknown
- 2021-07-19 JP JP2023503508A patent/JP2023537229A/ja active Pending
- 2021-07-19 EP EP21845882.6A patent/EP4181917A4/en not_active Withdrawn
- 2021-07-19 US US18/016,762 patent/US20240024337A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Okyay et al. | Another epidemic in the shadow of Covid 19 pandemic: a review of monkeypox | |
| JP2023528561A5 (cg-RX-API-DMAC7.html) | ||
| JP2011511754A5 (cg-RX-API-DMAC7.html) | ||
| Berry | Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System. | |
| LT5079B (lt) | Avies pararaupų viruso kamienų panaudojimas antivirusinių ir priešvėžinių vaistų gamybai | |
| Wang et al. | Enterovirus 71 induces autophagy in mice via mTOR inhibition and ERK pathway activation | |
| Gao et al. | Induction of SOCS expression by EV71 infection promotes EV71 replication | |
| JP2010530423A (ja) | 免疫活性化剤を用いたウイルス感染の早期介入 | |
| CN116251114A (zh) | 龙胆苦苷在制备防控病毒或细菌感染的药物中的应用 | |
| JP2003528925A5 (cg-RX-API-DMAC7.html) | ||
| JP2023518390A (ja) | ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 | |
| Denholm et al. | SARS-CoV-2-induced senescence as a potential therapeutic target | |
| CN106176700A (zh) | 氯硝柳胺在制备抗致瘤疱疹病毒药物中的应用 | |
| AU2023248776A1 (en) | A method of use for cannabidiol in the prevention and treatment of interferon-responsive conditions | |
| Stebbing et al. | Kaposi's sarcoma—an update | |
| CN102697832B (zh) | 金银花水提物和let-7a microRNA在制备预防及治疗登革病毒和登革热药物与保健品中的应用 | |
| Yuliia | MEDICAL SCIENCES | |
| Alhiti | Nanosilver plus Bacteriophages Cured COVID | |
| Haq | TYPE I INTERFERON: ANTIVIRAL IS NEED OF THE TIME FOR COVID-19 | |
| Li et al. | The effect of Gankang Suppository on duck hepatitis B virus, serum biochemistry and liver histology in ducklings | |
| US20230277650A1 (en) | Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv) | |
| Solanki et al. | Drug Development | |
| Abbaszadeh et al. | Bacteriophages: A possible choice for treatment of viral respiratory infections and COVID-19 | |
| Brandão et al. | Prolonged survival of rabid mice after treatment with Poly-ICLC Hiltonol® | |
| Mtewa et al. | SARS-CoV-2 vaccine development |